Skip navigation
Universidade Federal da Bahia |
Repositório Institucional da UFBA
Use este identificador para citar ou linkar para este item: https://repositorio.ufba.br/handle/ri/40790
Registro completo de metadados
Campo DCValorIdioma
dc.creatorFukuda, Thiago Gonçalves-
dc.date.accessioned2024-12-18T13:56:30Z-
dc.date.available2024-12-18T13:56:30Z-
dc.date.issued2024-11-08-
dc.identifier.citationFAKUDA, Thiago Gonçalves Fukuda Aspectos clínicos e prognósticos de pacientes com diagnóstico de doença do espectro da Neuromielite Óptica. Orientador: Jamary Oliveira Filho. 2024. 165 f. Tese (Doutorado em Ciências da Saúde) - Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, 2024.pt_BR
dc.identifier.urihttps://repositorio.ufba.br/handle/ri/40790-
dc.description.abstractIntroduction: Neuromyelitis optica spectrum disease (DENMO) is a rare inflammatory and demyelinating disease of the central nervous system (CNS), more frequent in women and people of African descent. No previous epidemiological or prognostic studies have been carried out in the region of the state of Bahia, northeastern Brazil. Objective: To identify demographic characteristics and factors associated with greater disease progression in patients with DENMO in the State of Bahia. Material and Methods: A single-center retrospective study was conducted with consecutive patients diagnosed with DENMO. Clinical and epidemiological characteristics were described. The degree of disability was expressed by the Expanded Disability Status Scale (EDSS). The main outcome of the study was the progression index, defined by the ratio between the EDSS and the duration of the disease in months. Predictors of disease progression were identified using negative binomial regression adjusted for disease duration. Results: Ninety-one patients were included, 72 (79.1%) of whom were female and 67 (73.6%) were of African descent. The mean age at onset was 36 (± 14) years and 73.3% were positive for the anti-aquaporin-4 antibody. Isolated transverse myelitis (32.9%) and isolated optic neuritis (22.4%) were the most frequent initial clinical syndromes. After multivariate analysis, optic neuritis (RR = 0.49; 95% CI=0.29 – 0.84; p = 0.009) and dyslipidemia (RR = 0.50; 95% CI=0.26 – 0.96; p= 0.038) were associated with slower disease progression. Involvement of the postrema area (RR = 6.59; 95% CI = 3.56 – 12.21; p < 0.001) and age at onset (RR = 1.01; 95% CI = 1.00 – 1.03; p = 0.047) were associated with a more rapid progression of the disease. Conclusions: In the first clinical and prognostic study in northeastern Brazil, we identified the involvement of the area postrema and the older age of onset as factors associated with the progression of the disease; and optic neuritis as the initial syndrome and dyslipidemia as the main protective factors.pt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal da Bahiapt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectTranstornos do espectro da neuromielite ópticapt_BR
dc.subjectNeuromielite Ópticapt_BR
dc.subjectAquaporina 4pt_BR
dc.subjectFatores prognósticospt_BR
dc.subjectPrognósticopt_BR
dc.subjectBrasil, Nordestept_BR
dc.subject.otherNeuromyelitis Opticapt_BR
dc.subject.otherAquaporin 4pt_BR
dc.subject.otherPrognosispt_BR
dc.subject.otherBrazil, Northeastpt_BR
dc.titleAspectos clínicos e prognósticos de pacientes com diagnóstico de doença do espectro da neuromielite ópticapt_BR
dc.typeTesept_BR
dc.publisher.programPós-Graduação em Ciências da Saúde (POS_CIENCIAS_SAUDE) pt_BR
dc.publisher.initialsUFBApt_BR
dc.publisher.countryBrasilpt_BR
dc.subject.cnpqCNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::NEUROLOGIApt_BR
dc.contributor.advisor1Oliveira Filho, Jamary-
dc.contributor.advisor1IDhttps://orcid.org/0000-0003-1915-0423pt_BR
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/0078761969684137pt_BR
dc.contributor.referee1Oliveira Filho, Jamary-
dc.contributor.referee1IDhttps://orcid.org/0000-0003-1915-0423pt_BR
dc.contributor.referee1Latteshttp://lattes.cnpq.br/0078761969684137pt_BR
dc.contributor.referee2Jesus, Pedro Antônio Pereira de-
dc.contributor.referee2IDhttps://orcid.org/0000-0003-1211-2272pt_BR
dc.contributor.referee2Latteshttp://lattes.cnpq.br/5480230512781945pt_BR
dc.contributor.referee3Sousa, Rafael Miranda-
dc.contributor.referee3IDhttps://orcid.org/0009-0004-6601-5341pt_BR
dc.contributor.referee3Latteshttp://lattes.cnpq.br/6500669235568142pt_BR
dc.contributor.referee4Cardoso, Eduardo Souza-
dc.contributor.referee4Latteshttp://lattes.cnpq.br/6450873093774669pt_BR
dc.contributor.referee5Pereira, Samira Luísa Apóstolos-
dc.contributor.referee5IDhttps://orcid.org/0000-0003-3493-1199pt_BR
dc.contributor.referee5Latteshttp://lattes.cnpq.br/3158829551542633pt_BR
dc.creator.IDhttps://orcid.org/0000-0002-7718-4288pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/9804568769181350pt_BR
dc.description.resumoIntrodução: A doença do espectro da neuromielite óptica (DENMO) é uma doença inflamatória e desmielinizante rara do sistema nervoso central (SNC), mais frequente em mulheres e afrodescendentes. Nenhum estudo epidemiológico ou prognóstico prévio foi realizado na região do estado da Bahia, Nordeste brasileiro. Objetivo: Identificar características demográficas e fatores associados a maior progressão da doença em pacientes com DENMO no Estado da Bahia. Material e Métodos: Foi realizado um estudo retrospectivo unicêntrico com pacientes consecutivos diagnosticados com DENMO. Foram descritas as características clínicas e epidemiológicas. O grau de incapacidade foi expresso pela Escala Expandida de Status de Incapacidade (EDSS). O desfecho principal do estudo foi o índice de progressão, definido pela razão entre o EDSS e a duração da doença em meses. Os preditores de progressão da doença foram identificados por meio de regressão binomial negativa ajustada para a duração da doença. Resultados: Noventa e um pacientes foram incluídos, sendo 72 (79,1%) do sexo feminino e 67 (73,6%) afrodescendentes. A média da idade de início foi de 36 (± 14) anos e 73,3% eram positivos para o anticorpo anti-aquaporina-4. Mielite transversal isolada (32,9%) e neurite óptica isolada (22,4%) foram as síndromes clínicas iniciais mais frequentes. Após análise multivariada, neurite óptica (RR = 0,49; IC 95%=0,29 – 0,84; p = 0,009) e dislipidemia (RR = 0,50; IC 95%=0,26 – 0,96; p= 0,038) foram associadas à progressão mais lenta da doença. O envolvimento da área postrema (RR = 6,59; IC 95% = 3,56 – 12,21; p < 0,001) e a idade de início (RR = 1,01; IC 95% = 1,00 – 1,03; p = 0,047) foram associados a uma progressão mais rápida da doença. Conclusões: No primeiro estudo clínico e prognóstico no nordeste do Brasil, identificamos o acometimento da área postrema e a idade mais avançada de início como fatores associados à progressão da doença; e a neurite óptica como síndrome inicial e a dislipidemia como os principais fatores protetores.pt_BR
dc.publisher.departmentFaculdade de Medicina da Bahiapt_BR
dc.relation.references1. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10(1):1–12. 2. De Seze J. Neuromyelitis optica. Arch Neurol [Internet]. 2003 Sep 1;60(9):1336–8. Available from: http://archneur.jamanetwork.com/article.aspx?doi=10.1001/archneur. 60.9.1336 3. Brain WR. Critical review: Disseminated sclerosis. Qjm [Internet]. 1930 Apr 1;os-23(91):343–91. Available from: https://academic.oup.com/qjmed/articlelookup/doi/10.1093/qjmed/os-23.91.343 4. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology [Internet]. 1999 Sep 1;53(5):1107–14. Available from: https://www.neurology.org/lookup/doi/10.1212/WNL.53.5.1107 5. Lennon PVA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–12. 6. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, 79 Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology [Internet]. 2006 May 23;66(10):1485–9. Available from: https://www.neurology.org/lookup/doi/10.1212/01.wnl.0000216139.4 4259.74 7. Bennett JL. Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. J Neuro-Ophthalmology [Internet]. 2016 Sep;36(3):238–45. Available from: https://journals.lww.com/00041327-201609000-00003 8. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89. 9. Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020;11(June):1–13. 10. Asgari N, Lillevang ST, Skejoe HPB, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76(18):1589–95. 11. Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, 80 Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016 May 1;79(5):775– 83. 12. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: A multicenter analysis. Arch Neurol. 2012;69(9):1176–80. 13. Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C, et al. Neuromyelitis optica in France: A multicenter study of 125 patients. Neurology. 2010;74(9):736–42. 14. Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, LaraRodríguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol [Internet]. 2009 Jan 9;256(1):35–44. Available from: http://link.springer.com/10.1007/s00415-009-0009-0 15. Alvarenga MP, Schimidt S, Alvarenga RP. Epidemiology of neuromyelitis optica in Latin America. Mult Scler J - Exp Transl Clin. 2017;3(3). 16. Rivera VM, Hamuy F, Rivas V, Gracia F, Rojas JI, Bichuetti DB, et al. Status of the neuromyelitis optica spectrum disorder in Latin America. Mult Scler Relat Disord. 2021;53. 17. Pereira FFCC, Pereira ABC, Alvarenga RMP, Vasconcelos CCF. The 81 prevalence of Neuromyelitis optica in a Brazilian City. J Neurol Sci [Internet]. 2015 Oct;357:e207. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022510X15012101 18. Lana-Peixoto MA, Talim NC, Pedrosa D, Macedo JM, SantiagoAmaral J. Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil. Mult Scler Relat Disord. 2021;50(November 2020). 19. Silva GD, Apóstolos-Pereira SL, Callegaro D. Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in São Paulo, Brazil. Mult Scler Relat Disord. 2023;70(December 2022):2022–4. 20. Alves CS, Santos FBC, Diniz DS. Correlation between Amerindian ancestry and neuromyelitis optica spectrum disorders (NMSOD) among patients in Midwestern Brazil. Arq Neuropsiquiatr. 2022;80(5):497–504. 21. Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91(22):E2089–99. 22. Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat 82 Disord [Internet]. 2019 Jan;27:412–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2211034818305303 23. Frigeri A, Gropper MA, Umenishi F, Kawashima M, Brown D, Verkman AS. Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. J Cell Sci [Internet]. 1995 Sep 1;108(9):2993–3002. Available from: https://journals.biologists.com/jcs/article/108/9/2993/24600/Localizat ion-of-MIWC-and-GLIP-water-channel 24. Ratelade J, Verkman AS. Neuromyelitis optica: Aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol [Internet]. 2012 Sep;44(9):1519–30. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1357272512002129 25. Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation. 2021;18(1):1–18. 26. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology [Internet]. 2007 Feb 20;68(8):603–5. Available from: https://www.neurology.org/lookup/doi/10.1212/01.wnl.0000254502.8 7233.9a 83 27. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LCS. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol [Internet]. 2008 Jan 1;126(1):12–6. Available from: http://archopht.jamanetwork.com/article.aspx?doi=10.1001/archophth almol.2007.26 28. Dutra BG, Da Rocha AJ, Nunes RH, Maia ACM. Neuromyelitis optica spectrum disorders: Spectrum of MR imaging findings and their differential diagnosis. Radiographics. 2018;38(1):169–93. 29. Merle H, Olindo S, Donnio A, Richer R, Smadja D, Cabre P. Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica. Investig Ophthalmol Vis Sci [Internet]. 2008 Oct 1;49(10):4412–7. Available from: http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.08-1815 30. Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, et al. Short Myelitis Lesions in Aquaporin-4-IgG– Positive Neuromyelitis Optica Spectrum Disorders. JAMA Neurol [Internet]. 2015 Jan 1;72(1):81. Available from: http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneur ol.2014.2137 31. Sato D, Fujihara K. Atypical presentations of neuromyelitis optica. 84 Arq Neuropsiquiatr. 2011;69(5):824–8. 32. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65(9):1479–82. 32. Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: A herald of acute exacerbations. J Neurol Neurosurg Psychiatry. 2008;79(9):1075–8. 33. Iorio R, Lucchinetti CF, Lennon VA, Farrugia G, Pasricha PJ, Weinshenker BG, et al. Intractable Nausea and Vomiting From Autoantibodies Against a Brain Water Channel. Clin Gastroenterol Hepatol [Internet]. 2013 Mar;11(3):240–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1542356512014218 34. Hyun JW, Kwon YN, Kim SM, Lee HL, Jeong WK, Lee HJ, et al. Value of Area Postrema Syndrome in Differentiating Adults With AQP4 vs. MOG Antibodies. Front Neurol. 2020;11. 35. Okada K, Kobata M, Naruke S. Neuromyelitis optica spectrum disorder with area postrema syndrome. Neurol Clin Pract [Internet]. 2019 Apr;9(2):173–5. Available from: https://cp.neurology.org/lookup/doi/10.1212/CPJ.0000000000000586 85 36. Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler J [Internet]. 2014 Jun 7;20(7):843–7. Available from: http://journals.sagepub.com/doi/10.1177/1352458513507822 37. Etemadifar M, Nouri H, Khorvash R, Salari M, Ghafari K, Aghababaee A. Frequency of diencephalic syndrome in NMOSD. Acta Neurol Belg [Internet]. 2022 Aug 13;122(4):961–7. Available from: https://link.springer.com/10.1007/s13760-021-01792-1 38. Kim W, Kim SH, Hyun Lee S, Feng Li X, Jin Kim H. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler J. 2011;17(9):1107–12. 39. Cabre P. Do modern therapies change natural history of Neuromyelitis optica? Rev Neurol (Paris) [Internet]. 2021;177(5):567–70. Available from: https://doi.org/10.1016/j.neurol.2020.07.002 40. Queiroz ALG de, Soares Neto HR, Kobayashi TT, Silva SMC de A. Plasma exchange in inflammatory demyelinating disorders of the central nervous system: reasonable use in the clinical practice. Arq Neuropsiquiatr [Internet]. 2023 Mar 14;81(03):296–307. Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042- 86 1758447 41. Bichuetti DB, Perin MM de M, Souza NA de, Oliveira EML de. Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult Scler J [Internet]. 2019 Jul 15;25(8):1150–61. Available from: http://journals.sagepub.com/doi/10.1177/1352458518776584 42. Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol [Internet]. 2020;19(4):298– 306. Available from: http://dx.doi.org/10.1016/S1474- 4422(20)30066-1 43. Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a doubleblind, randomised placebo-controlled phase 2/3 trial. Lancet [Internet]. 2019;394(10206):1352–63. Available from: http://dx.doi.org/10.1016/S0140-6736(19)31817-3 44. Duchow A, Bellmann-Strobl J. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegener Dis Manag [Internet]. 2021 Feb;11(1):49–59. Available from: 87 https://www.futuremedicine.com/doi/10.2217/nmt-2020-0046 45. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–25. 46. Pittock SJ, Barnett M, Bennett JL, Berthele A, de Sèze J, Levy M, et al. Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol [Internet]. 2023 Apr 5; Available from: https://onlinelibrary.wiley.com/doi/10.1002/ana.26626 47. JF K. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;Nov;33(11):1444-52. 48. Cendrowski WS. Progression index and disability status in multiple sclerosis: a resurvey of 207 patients in central Poland. Schweiz Arch Neurol Psychiatr [Internet]. 1986;137(4):5–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2428106 49. Bichuetti DB, Oliveira EML, Souza NA, Rivero RLM, Gabbai AA. Neuromyelitis optica in Brazil: A study on clinical and prognostic factors. Mult Scler. 2009; 50. Etemadifar M, Dashti M, Vosoughi R, Abtahi SH, Ramagopalan S V., Nasr Z. An epidemiological study of neuromyelitis optica in 88 Isfahan. Mult Scler J. 2014;20(14):1920–2. 51. Del Negro MC, Marinho PBC, Papais-Alvarenga RM. Neuromyelitis optica: phenotypic characteristics in a Brazilian case series. Arq Neuropsiquiatr. 2017;75(2):81–6. 52. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology. 2015; 53. Bukhari W, Clarke L, O’Gorman C, Khalilidehkordi E, Arnett S, Prain KM, et al. The clinical profile of NMOSD in Australia and New Zealand. J Neurol [Internet]. 2020;267(5):1431–43. Available from: https://doi.org/10.1007/s00415-020-09716-4 54. Maria A, Zanette D, Gonc MDS, Bahia S, Vasconcelos L, Nogueira A, et al. SICKLE CELL ANEMIA : DELAYED DIAGNOSIS IN BAHIA , BRAZIL - … the results of neonatal screening have shown that in Bahia , 1 in 650 children are born each year with SCD , a higher prevalence than any. Ethn Dis. 2011;21(71):243–7. 55. Domingos J, Isidoro L, Figueiredo R, Brum M, Capela C, Barros P, et al. Neuromyelitis optica in Portugal (NEMIPORT) - A multicentre study. Clin Neurol Neurosurg [Internet]. 2015;134:79–84. Available from: http://dx.doi.org/10.1016/j.clineuro.2015.04.001 89 56. Amaral JM, Talim N, Kleinpaul R, Lana-Peixoto MA. Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord [Internet]. 2020;41(March):102045. Available from: https://doi.org/10.1016/j.msard.2020.102045 57. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibodypositive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(6):1834–49. 58. Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, MecaLallana JE, Oreja-Guevara C, et al. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol NeuroInflammation. 2016;3(3):1–9. 59. ERC et al F. Recomendações no tratamento da Esclerose Múltipla e Neuromielite Óptica. Editora e Eventos Omnifarma, editor. São Paulo: Departamento Científico de Neuroimunologia da ABN; 2016. 60. Kang H, Chen T, Li H, Xu Q, Cao S, Wei S. Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. J Neurol. 2017; 61. Ambika S, Balasubramanian M, Theresa L, Veeraputhiran A, 90 Arjundas D. Aquaporin 4 antibody [NMO Ab] status in patients with severe optic neuritis in India. Int Ophthalmol. 2015; 62. Waters P, Akman-demir G, Tu E, Jarius S, Mutlu M, Ku M, et al. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. 2011;464–70. 63. Bichuetti DB, Falcão AB, Boulos F de C, Morais MM de, Lotti CB de C, Fragomeni M de O, et al. The profile of patients followed at the Neuroimmunology Clinic at UNIFESP: 20 years analysis. Arq Neuropsiquiatr. 2015;73(4):304–8. 64. Shahmohammadi S, Doosti R, Shahmohammadi A, Mohammadianinejad SE, Sahraian MA, Azimi AR, et al. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult Scler Relat Disord. 2019;27(November 2018):350–63. 65. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology. 2003;60(5):848–53. 66. Bergamaschi R, Ghezzi A. Devic’s neuromyelitis optica: Clinical features and prognostic factors. Neurol Sci. 2004; 67. Papathanasiou A, Tanasescu R, Tench CR, Rocha MF, Bose S, 91 Constantinescu CS, et al. Age at onset predicts outcome in aquaporin4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. J Neurol Sci. 2021;431(September):120039. 68. Wang KC, Lee CL, Chen SY, Lin KH, Tsai CP. Prominent brainstem symptoms/signs in patients with neuromyelitis optica in a Taiwanese population. J Clin Neurosci. 2011;18(9):1197–200. 69. Lu Z, Qiu W, Zou Y, Lv K, Long Y, You W, et al. Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica. J Neurol Sci. 2010;293(1–2):92–6. 70. Wang Y, Zhang L, Zhang B, Dai Y, Kang Z, Lu C, et al. Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. J Neurol. 2014;261(5):954–62. 71. Wang Y, Wu A, Chen X, Zhang L, Lin Y, Sun S, et al. Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy. BMC Neurol. 2014;14(1):1–7. 72. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An 92 amnesic process. Brain. 2003;126(4):770–82. 73. Tintoré M, Rovira A, Rio J, Nos C, Grivé E, Téllez N, et al. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol. 2005;57(2):210–5. 74. Wu K, Wen LL, Duan R, Li Y, Yao Y, Jing L, et al. Triglyceride Level Is an Independent Risk Factor in First-Attacked Neuromyelitis Optica Spectrum Disorders Patients. Front Neurol. 2019;10(November):1–9. 75. S. Antonopoulos A, Margaritis M, Lee R, Channon K, Antoniades C. Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials. Curr Pharm Des. 2012;18(11):1519–30. 76. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J Lipid Res. 2004;45(7):1169–96.pt_BR
dc.type.degreeDoutoradopt_BR
Aparece nas coleções:Tese (PPgCS)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Tese_Final_161224.pdfTese Doutorado - Thiago Fukuda37,38 MBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.